• E-mail :[email]
  • Phone : +33 1 53 98 80 20
  • Location : Paris, France
Last update 2019-06-26 10:08:35.411

jean-philippe empana MD PhD

Course and current status

Position

Since 2006, Full time researcher at INSERM (fixed position)

Currently INSERM Research Director (DR2) and co-director of Team 4 "Integrative Epidemiology of Cardiovascular Disease" at the Paris Cardiovascular Research Centre, INSERM U970

 

Diploma

2009 HDR (Hability to Direct Research), Paris, France

2005 PhD degree in Epidemiology and Public Health, Paris

1996-2001 Internship in Public Health, Lille, France  

1988-1995 Studies of Medicine, Lyon, France 

 

Teams:

Sept 2009- INSERM U970, team 4 "Integrative Epidemiology of Cardiovascular Disease"

2007-2009 INSERM U909

2002-2007 INSERM AVENIR team, Paris

Scientific summary

I am co-directing with X Jouven, a 45 staff members multidisciplinary team dedicated to the epidemiology of cardiovascular disease and its complications. A total of 4 research topics are addressed and include 1) the epidemiology of cardiac arrest; 2) the place of novel biomarkers for CVD risk prediction; 3) the epidemiology of CVD in sub saharian african countries; and 4) the determinants of antibody mediated rejection in heart transplant. 

More specifically, I am coordinating the Paris Prospective study III, a prospective cohort study that has included 10 166 participants who have been followed up every two years for 10 years now. We are interested in the predictive power of heart rate parameters (2h of recordings), carotid artery stiffness parameters and measures of the baroreflex sensitivity (carotid echotracking) together with novel circulating blood biomarkers (a large biobank of 200 000 baseline samples is available) for incident CVD and cancer.

I am also leading a collaborative and international research programme on the clinical relevance of a novel concept of prevention of CVD, i.e. primordial prevention. This approach aims to prevent the onset of risk factors of CVD in the first place. We have recently demonstrated the relevance of this approach for CVD and non CVD outcomes including dementia, suggesting that this concept may be helpful for a global prevention of chronic diseases. This project is developped though several national and international collaborations including the Three City Study (France), the Whitehall II study (UK), the Maastricht study (the Netherlands) and the CoLaus study (Switzerland).

With X Jouven, we are partners and WP leaders of a H2020 programme (ESCAPENET) on the epidemiology of cardiac arrest in 16 European countries. Finally, I am an active member of the Paris Transplant Group led by A Loupy. This is an international and multidisciplinary network investigating the determinants of antibody mediating rejection in the field of renal and heart transplant. We are currently coordinating 1 H2020 (EUTRAIN) and 1 RHU (national grants for clinical research programmes, KTD Innov) on this topic.  

Image d’exemple